Deep Vein Thrombosis (DVT) News and Research

RSS
Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Study reports that delaying surgery post-COVID-19 reduces the risk of postoperative cardiovascular issues

Study reports that delaying surgery post-COVID-19 reduces the risk of postoperative cardiovascular issues

Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications

Large COVID vaccination study found that thrombosis and thrombocytopenia are very rare complications

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Paxlovid antiviral therapy reduces risk of long COVID

Paxlovid antiviral therapy reduces risk of long COVID

Study sheds new light on the risk of rare blood-clotting condition after covid-19 vaccination

Study sheds new light on the risk of rare blood-clotting condition after covid-19 vaccination

Marijuana-dependent patients may face higher infection rates following knee and shoulder arthroscopy

Marijuana-dependent patients may face higher infection rates following knee and shoulder arthroscopy

Study suggests strategies to bolster the administration of clot-busting drugs

Study suggests strategies to bolster the administration of clot-busting drugs

French study on cardiovascular disease incidence during COVID pandemic and vaccination campaign

French study on cardiovascular disease incidence during COVID pandemic and vaccination campaign

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

UNC researcher working with NASA to study blood clot formation in astronauts during space missions

UNC researcher working with NASA to study blood clot formation in astronauts during space missions

Role of complement factor H-related protein 5 in venous thromboembolism and COVID-19

Role of complement factor H-related protein 5 in venous thromboembolism and COVID-19

Cancer patients with non-O blood types face higher risk of developing blood clots

Cancer patients with non-O blood types face higher risk of developing blood clots

New AI algorithm may quickly, effectively diagnose deep vein thrombosis

New AI algorithm may quickly, effectively diagnose deep vein thrombosis

May-Thurner anatomy common in patients with CTEPH, new study shows

May-Thurner anatomy common in patients with CTEPH, new study shows

Assessing the risks of thrombotic events post vaccination with ChAdOx1 and BNT162b2 vaccines in England

Assessing the risks of thrombotic events post vaccination with ChAdOx1 and BNT162b2 vaccines in England

CHEST releases new clinical guidelines for management of venous thromboembolism

CHEST releases new clinical guidelines for management of venous thromboembolism

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.